General Rodríguez - Argentina | Vicente López - Argentina
vetanco@vetanco.com | vetancoargentina@vetanco.com
A history
built on
science, people
and purpose
Since 1987, Vetanco has grown without
losing sight of what matters most:
our closeness to the field and our
commitment to producers.
Jorge Winokur and Horacio Mancini, friends from the University of Buenos Aires, found Vetanco SA with the support of Carlos Winokur and the expertise of chemist Dr. Oscar Barletta. The first product: the local synthesis of Enrofloxacin, which at the time was only produced by major global laboratories.
Vetanco achieves the first synthesis of a veterinary quinolone in Latin America, establishing its research and development DNA.
The launch of Ivermectin hydrogenation: another breakthrough that cements the company’s scientific reputation.
Initial exports to Southeast Asia. Vetanco begins to prove that Argentine science can reach across the globe.
Vetanco lands in Brazil, initially in São Paulo, soon relocating to Chapecó, Santa Catarina, upon the recommendation of Dr. Ricardo Soncini. It becomes the first Argentine animal health company to secure a significant foothold in the Brazilian market.
Inauguration of the production plant in Villa Martelli, Argentina, expanding manufacturing capacity to meet regional growth.
Foundation of Vetanco Uruguay alongside Dr. José Luis Bruzzone, marking the beginning of structured expansion across the Americas.
Foundation of Vetanco Panama, opening the door to Central America and the Caribbean.
Inauguration of the manufacturing plant in Chapecó, Brazil. Foundation of Vetanco Dominican Republic. Vetanco receives its first Argentine Exportar Award, an official recognition of the company’s export capacity and global innovation.
Vetanco achieves Good Manufacturing Practices (GMP) certification, elevating its standards to meet the requirements of the world’s most demanding markets.
Foundation of Vetanco Costa Rica, consolidating the company’s presence in Central America.
The Argentine government reiterates its recognition of Vetanco’s successful export track record.
Researcher Sherry Layton joins Vetanco to lead the development of innovative products in the vaccine line.
Foundation of Vetanco Mexico. Inauguration of the General Rodríguez mega-plant (33,000 m², 1,000 tons/month, SENASA certified). The birth of Bioinnovo: the first technology-based public-private partnership between INTA (Argentina’s national agricultural research institute) and a private company in Argentina: a global milestone. Third Exportar Award.
Vetanco launches its biologicals line, sparking a new era of innovative vaccines for food-producing animals.
Foundation of Vetanco Colombia. Creation of BV Science, a global partner with Dr. Bata Company (Hungary), uniting R&D, marketing, and technical support. Bioinnovo receives the Innovar Award from the Argentine Ministry of Science and the Motivar Award in the Business Innovation category.
Foundation of Vetanco USA. Bioinnovo wins the CiTA Award for developing IgY DNT (an antibody-based therapy), the first approved biological product to prevent neonatal diarrhea in calves..
Foundation of Vetanco Guatemala. Launch of Biotech Vac Salmonella in Brazil, the world’s first subunit vaccine administered via drinking water for Salmonella control in poultry.
Launch of the Xponential Meeting, an exclusive event for C-level executives in the animal protein market, positioning Vetanco among the industry’s key strategic voices.
Vetanco ranks as the 37th largest animal health company in the world by revenue. Dr. Bata Company inaugurates its own manufacturing facility in Chapecó, Brazil.
Researcher Dr. Mariano Miyakawa joins Vetanco to lead the development of innovative in-feed products and Vetanco becomes the 35th largest animal health company in the world by global revenue.
Dr. Mike Kogut, following 34 years at the USDA, joins Vetanco to develop products focused on host defense. Inauguration of the BV Lab, a public-private partnership between BV Science and UDESC, a new benchmark public-private partnership in Santa Catarina, Brazil. New corporate office opens in Chapecó.
Four decades of building science, partnerships, and results. The story continues.
Mission 
Vision 
Values 
Continuous innovation.
Decentralized and collaborative research.
Integrity and ethics.
Culture of belonging.
Responsible autonomy.
Vetanco operates in over 40 countries with its own branches and distributors, specialized technical teams, and a portfolio tailored to the specific demands of each market. A multinational structure built over decades, without ever losing the closeness to the field that has defined us since 1987.
Founded in 1987 in Buenos Aires, Vetanco began with a focus on poultry and swine production and grew through scientific milestones that helped define its reputation: the synthesis of the first veterinary quinolone in Latin America in 1990, the hydrogenation of Ivermectin in 1993, and the first exports to Southeast Asia in 1995.
Over time, this expertise also expanded into cattle production, with solutions developed to support the different realities of the sector. Vetanco builds on constant dialogue with the field and on an understanding of factors such as production systems, geography and management practices to apply science that respects the pace of each herd and contributes to its health and productivity.
As Argentina’s leading exporter of veterinary pharmaceuticals, Vetanco received the Fundación Exportar Award in 2007 and 2010 and obtained Good Manufacturing Practices certification from SENASA, Argentina’s national authority for animal health and agri-food quality, in 2008.
The headquarters in Vicente López and the industrial plant in General Rodríguez, with 33,000 m² of internationally certified production capacity, remain at the center of the company’s global operations.
Founded in 2001, Vetanco Brazil continues its expansion in the veterinary market, offering highly differentiated products and top-tier technical support. With a team operating across all Brazilian states, Vetanco Brazil provides on-farm support and technical assistance to clients nationwide.
Since entering Brazil, Vetanco has solidified its position as a robust player in the veterinary sector, becoming a key supplier for major agribusinesses and standing out in industry events. In 2007, the branch achieved ISO 9001 certification, reinforcing its commitment to Quality Management Systems and continuous improvement in customer service.
Chapecó is also home to the dedicated Dr. Bata manufacturing plant, inaugurated in 2023.
Mexico represents Vetanco’s expansion into North America, one of the fastest-growing animal protein markets in Latin America, with operations based in Querétaro.
Supported by the same scientific milestones and certifications that have shaped the company’s global journey, including Good Manufacturing Practices recognized by SENASA and the Fundación Exportar Awards received in 2007 and 2010, the Mexican subsidiary offers solutions for poultry, swine and cattle production, backed by local technical support and regulatory compliance for the North American market.
In cattle production, Vetanco develops solutions based on a constant understanding of field needs, recognizing that each production system has its own pace, shaped by factors such as geography, management practices and the specific characteristics of each operation. Science is adapted to these realities to support herd health and productivity without imposing a single model.
Vetanco Colombia operates with its own structure in one of South America’s fastest-growing markets.
Building on the biotechnological portfolio developed since 1987 and the international certifications that positioned Vetanco as Argentina’s top exporter of veterinary pharmaceuticals, the Colombian operation delivers specialized animal health solutions, backed by a local technical team and customized customer service.
In Uruguay, Vetanco operates through Irdenco S.A., a strategic partner based in Montevideo.
Our presence in the country brings the Uruguayan market the same scientific portfolio and quality standards that have made Vetanco a benchmark in Latin American animal health, supported by a partnership consolidated over many years.
Our presence in the U.S. holds a strategic dimension that goes beyond commercial sales: the University of Minnesota is home to Vetanco’s advanced R&D laboratory, deeply integrated into the North American biotechnological innovation ecosystem.
The country also hosts BV Science, Inc., the joint venture created in 2018 with Dr. Bata Ltd., based in St. Louis, Missouri. The commercial operation, Vetanco USA, Inc., registers products and fosters relationships within one of the world’s most demanding regulatory landscapes.
For Vetanco, being in the U.S. means being at the forefront of the future of animal biotechnology.
Vetanco serves Central America and the Caribbean through Avifarm S.A., headquartered in Panama City, and Vetanco Guatemala S.A.
These regional operations bring the local market the animal health portfolio developed since 1987, delivering the technical support and quality standards that have positioned Vetanco as a leader in Latin American animal production.
Region (VETANCO/GLOBAL)
by
